Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 6/20 | 0.36 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6755263 | 1.00 | NR3C1 (0.42) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL7113336 | 1.00 | NR3C1 (0.42) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL6753119 | 0.90 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4815312 | 0.90 | NR3C1 (0.41) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818856 | 0.83 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4818843 | 0.83 | NR3C1 (0.43) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL5197110 | 0.82 | CYP19A1 (0.36) | NR3C1ARPGRNR3C2CYP19A1 | |
| SCHEMBL4255031 | 0.80 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4982043 | 0.80 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR | |
| SCHEMBL4822515 | 0.80 | NR3C1 (0.44) | NR3C1TDP1MEN1KMT2AAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487859-B1 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN CO LLC (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1539795-A1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA-(5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | Pharmacia & Upjohn Company LLC (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1487859-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-22 | — | — | EP | claimed |
| US-20040127702-A1 | intermediates to produce the pharmaceutically useful compound eplerenone | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| WO-2004037844-A1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-06 | — | — | WO | claimed |
| WO-2003082895-A2 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN COMPANY (US) | 2003-10-09 | — | — | WO | claimed |
| US-7417140-B2 | 17 beta -Hydroxy-7 alpha -(2'-hydroperoxy-2'-methoxyacetyl)pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone chemical intermediate useful to prepare eplerenone a hypotensive agent, useful for treating congestive heart failure | PFIZER INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7414127-B2 | used to prepare eplerenone; intermediates | PFIZER INC. (US) | 2008-08-19 | — | — | US | disclosed |
| EP-1487859-B1 | PROCESS TO PREPARE EPLERENONE | PHARMACIA & UPJOHN CO LLC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7411062-B2 | 17-Beta -hydroxy-7-alpha-(2'-oxoacetyl or alkanoylcarbonyl)-pregna-4,9(11)-dien-3-one-21-carboxylic acid, gamma -lactone; intermediate for preparing eplerenone | PFIZER INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1539795-B1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA-(5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN CO LLC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1539795-B1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA-(5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN CO LLC (US) | 2007-10-31 | — | — | EP | disclosed |
| EP-1539795-B1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA-(5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN CO LLC (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20040127702-A1 | intermediates to produce the pharmaceutically useful compound eplerenone | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| WO-2004037844-A8 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | UPJOHN CO (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004037844-A8 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | UPJOHN CO (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040097475-A1 | Reacting steroid intermediate with nucleophilic reagent in presence of Lewis acid catalyst to produce 7-substituted steroid compound | PHARMACIA & UPJOHN COMPANY | 2004-05-20 | — | — | US | disclosed |
| WO-2004037844-A1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037844-A1 | CRYSTALLINE 17BETA-HYDROXY-7ALPHA- (5'-METHYL-2'-FURYL)-PREGNA-4,9(11)-DIEN-3-ONE-21-CARBOXYLIC ACID, GAMMA-LACTONE | PHARMACIA & UPJOHN COMPANY (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | PHARMACIA & UPJOHN COMPANY | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127702-A1 | intermediates to produce the pharmaceutically useful compound eplerenone | HSD17B7, CYP11B1, CYP17A1 | NR3C1 54/4885TDP1 4837/4885MEN1 277/4885 |
| US-20030232981-A1 | Contacting a Delta 3,5-3-enol ether of formula (alkyl enol ether) with a hydride abstractor and an alcohol | NR3C2, HSD3B2, HSD11B2 | NR3C1 19/4885TDP1 4733/4885MEN1 664/4885 |
| US-20040097475-A1 | Reacting steroid intermediate with nucleophilic reagent in presence of Lewis acid catalyst to produce 7-substituted steroid compound | CYP17A1, HSD17B7, NR5A1 | NR3C1 25/4885TDP1 4798/4885MEN1 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.